Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer

Glenn M. Cannon, Patrick Walsh, Alan Wayne Partin, Charles R. Pound

Research output: Contribution to journalArticle

Abstract

After primary treatment for clinically localized prostate cancer, biochemical recurrence is usually the first evidence of either local recurrence or metastatic progression. This poses a diagnostic dilemma for both the patient and the physician regarding future therapy. Prostate-specific antigen doubling time (PSADT) is a useful tool in this clinical setting. There have been multiple reports of the utility of PSADT in men with isolated biochemical recurrence after either radical prostatectomy or external-beam radiation therapy. Early observations of PSADT in men with recurrence are reviewed and the current literature is summarized to allow physicians to make an accurate assessment of a patient's risk of progression after isolated biochemical recurrence.

Original languageEnglish (US)
Pages (from-to)2-8
Number of pages7
JournalUrology
Volume62
Issue numberSUPPL. 1
DOIs
StatePublished - 2003

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Recurrence
Physicians
Therapeutics
Prostatectomy
Radiotherapy

ASJC Scopus subject areas

  • Urology

Cite this

@article{895c459bccce4c17a285e379ebfc7e2a,
title = "Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer",
abstract = "After primary treatment for clinically localized prostate cancer, biochemical recurrence is usually the first evidence of either local recurrence or metastatic progression. This poses a diagnostic dilemma for both the patient and the physician regarding future therapy. Prostate-specific antigen doubling time (PSADT) is a useful tool in this clinical setting. There have been multiple reports of the utility of PSADT in men with isolated biochemical recurrence after either radical prostatectomy or external-beam radiation therapy. Early observations of PSADT in men with recurrence are reviewed and the current literature is summarized to allow physicians to make an accurate assessment of a patient's risk of progression after isolated biochemical recurrence.",
author = "Cannon, {Glenn M.} and Patrick Walsh and Partin, {Alan Wayne} and Pound, {Charles R.}",
year = "2003",
doi = "10.1016/j.urology.2003.09.009",
language = "English (US)",
volume = "62",
pages = "2--8",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer

AU - Cannon, Glenn M.

AU - Walsh, Patrick

AU - Partin, Alan Wayne

AU - Pound, Charles R.

PY - 2003

Y1 - 2003

N2 - After primary treatment for clinically localized prostate cancer, biochemical recurrence is usually the first evidence of either local recurrence or metastatic progression. This poses a diagnostic dilemma for both the patient and the physician regarding future therapy. Prostate-specific antigen doubling time (PSADT) is a useful tool in this clinical setting. There have been multiple reports of the utility of PSADT in men with isolated biochemical recurrence after either radical prostatectomy or external-beam radiation therapy. Early observations of PSADT in men with recurrence are reviewed and the current literature is summarized to allow physicians to make an accurate assessment of a patient's risk of progression after isolated biochemical recurrence.

AB - After primary treatment for clinically localized prostate cancer, biochemical recurrence is usually the first evidence of either local recurrence or metastatic progression. This poses a diagnostic dilemma for both the patient and the physician regarding future therapy. Prostate-specific antigen doubling time (PSADT) is a useful tool in this clinical setting. There have been multiple reports of the utility of PSADT in men with isolated biochemical recurrence after either radical prostatectomy or external-beam radiation therapy. Early observations of PSADT in men with recurrence are reviewed and the current literature is summarized to allow physicians to make an accurate assessment of a patient's risk of progression after isolated biochemical recurrence.

UR - http://www.scopus.com/inward/record.url?scp=1842840810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842840810&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2003.09.009

DO - 10.1016/j.urology.2003.09.009

M3 - Article

C2 - 14747037

AN - SCOPUS:1842840810

VL - 62

SP - 2

EP - 8

JO - Urology

JF - Urology

SN - 0090-4295

IS - SUPPL. 1

ER -